This CEO wants to cover weight loss drugs for employees. They're just too expensive. - BERITAJA

For Dr. Joseph Cacchione, the mathematics connected GLP-1 drugs stopped making sense.

The CEO of the Philadelphia-based nonprofit infirmary strategy Jefferson said his statement now spends much connected medicine supplier sum — fueled by the soaring usage of weight nonaccomplishment medications for illustration Wegovy and Zepbound — than it does connected inpatient care.

Jefferson has dozens of hospitals crossed the region. It besides has its ain security scheme for its 65,000 employees.

A decade ago, medicine narcotics made up about 14% of Jefferson’s security spending, Cacchione said.

Last year, it was 40%. In 2025, Jefferson’s security limb reported about a $180 cardinal loss, about a 3rd of which was driven by sum of GLP-1s, the CEO said.

He was forced to laic disconnected much than 600 labor arsenic supplier sum ate up operating costs. This year, the security scheme started requiring labor to spell done fare and manner programs earlier it would cover GLP-1 narcotics for weight loss — a regularisation Cacchione said has already saved Jefferson $20 million.

“We understand the worth of them, but they are putting a large accent connected the system,” he said. “The strategy wants to salary for them. We conscionable can’t spend to salary for them correct now.”

Exactly what insurers and employers salary for GLP-1s is difficult to pin down. Currently, the monthly database value for Novo Nordisk’s Wegovy is $1,349 and for Eli Lilly’s Zepbound, $1,086. But security plans don’t salary that amount, acknowledgment to discounts and rebates.

According to Blue Cross Blue Shield, the nett value for employer-sponsored sum of GLP-1s ranges from $617 to $766 a period per employee. (Bigger discounts are disposable for patients who forgo security wholly and salary for the narcotics retired of pocket, but these prices don’t impact what insurers and employers pay.)

In a statement, a Lilly spokesperson said the institution is taking steps to get much employers to screen GLP-1 medications, including a caller programme that lowers the costs for group pinch job-based insurance.

Novo Nordisk announced past period that, starting successful 2027, it will cut Wegovy’s database value by half, to $675.

Cacchione said it’s still not enough. “I deliberation they’re going to person to travel down much than half,” he said. “But half is simply a awesome start.”

More employers restrict entree

Jefferson’s acquisition is portion of a increasing dilemma crossed the U.S. wellness attraction system. As demand for GLP-1 narcotics surges, employers and insurers are struggling to support up pinch the cost, pinch immoderate plans scaling backmost sum aliases dropping it altogether.

A survey from KFF, a nonprofit wellness argumentation investigation group, recovered galore ample employers are tightening entree to GLP-1 drugs. In 2025, about 1 successful 5 companies pinch astatine slightest 200 workers covered the medications for weight loss, rising to about 1 successful 2 of the largest companies.

However, about a 3rd of the employers that covered the narcotics required workers to effort fare aliases manner programs first — up from conscionable 10% a twelvemonth earlier.

“Employers were universally telling america they ended up spending much than they thought they would and it was a large daze to their medicine supplier spending,” said Matt Rae, the subordinate head of the Program connected the Health Care Marketplace astatine KFF.

The accrued spending was melodramatic for Jefferson.

“The uptake was very quick,” Cacchione said.

He said the move to restrict entree to the narcotics was aimed astatine limiting what he described arsenic “casual” use.

If you are dealing pinch bills that look to beryllium retired of statement aliases a denial of coverage, attraction aliases repairs, whether for health, location aliases auto, please email america astatine Costofdenial@nbcuni.com.

Short-term usage of GLP-1 medications has go wide complete the past respective years, said Dr. Christopher McGowan, a gastroenterologist who runs a weight nonaccomplishment session successful Cary, North Carolina.

It began, McGowan said, pinch the off-label usage of glucosuria narcotics for illustration Ozempic and Mounjaro for weight nonaccomplishment and accelerated pinch the emergence of cheaper compounded versions, which are fundamentally copycat versions of the narcotics made by pharmacists.

“For an individual, that whitethorn beryllium a worthwhile trade-off,” McGowan said. “But for a wellness strategy aliases insurer, it intends paying a precocious value for a impermanent result.”

Cacchione said immoderate labor wanted to driblet 15 aliases 20 pounds.

They say, “‘I’m a small overweight. I’m getting married. I want to driblet 15 aliases 20 pounds.’ They spell correct connected the GLP-1s,” he said.

Liz Skrbkova, a spokesperson for Novo Nordisk, said a increasing assemblage of investigation shows the wellness benefits of GLP-1 narcotics could construe into semipermanent savings for employers and the economy. She pointed to a 2025 report from the Institute for Clinical and Economic Review, which recovered that Wegovy is cost-effective connected an individual level because it could dainty obesity, glucosuria and different conditions. However, because the U.S. has precocious rates of obesity, the value whitethorn still origin strain connected wellness systems’ budgets.

Cacchione said he understands the arguments about GLP-1s and semipermanent wellness attraction costs. The medications person been approved to trim the consequence of bosom attacks and strokes, slow the progression of kidney illness and dainty slumber apnea.

“There’s nary mobility that they will person a return connected investment,” Cacchione said, ”but who pays for them successful the twelvemonth that you present them?”

“Who pays that $15,000 truthful I could prevention money 10 years from now?” he added. “We haven’t answered that question, and it becomes, is the employer consenting to do that? Because if the employer is not consenting to do it, it’s going to autumn connected the patient.”